Madrigal Pharmaceuticals(MDGL)
WEST CONSHOHOCKEN, PAPharmaceutical
Focus: Madrigal is a public-stage specialty pharmaceutical company focused on small-molecule therapeutics in neurology and metabolic liver disease. They have achieved commercial traction with REZDIFFRA (resmetirom), their thyroid hormone receptor beta agonist approved for MASH.
Profile data last refreshed 59m ago · AI intelligence enriched 1w ago
Funding Stage
PUBLIC
Open Jobs
63+49 this month
Hot — 65 jobs added in 30d
Net +49 (65 new, 16 removed). Aggressive expansion phase.
Should You Work at Madrigal Pharmaceuticals?
AI assessmentStrong near-term career opportunity if you can tolerate pre-profitability risk; best suited for professionals seeking commercial-stage upside and willing to ride a cash-constrained biotech through pipeline inflection.
Why Work Here
- Commercial momentum: Recent earnings beat and MASH drug sales driving top-line growth signals validated market fit and sales infrastructure scaling (8 commercial roles open)
Data completeness
7/9 — Strong
Company HealthStrong
Pipeline
Late-stage
4 Phase 3+
LOE Risk
Protected
No near-term cliffs
Hiring
Stable
Revenue
$0K
Key Products
Help build intelligence for Madrigal Pharmaceuticals
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.